Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
British Journal of Haematology
|
September 10, 2011
KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts
Hirokazu Miki, Shuji Ozaki, Shingen Nakamura, et al.
Haematologica
|
June 27, 2020
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma
Keiichiro Watanabe, Ariunzaya Bat-Erdene, Hirofumi Tenshin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 2017
Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Yongxian Hu, Zhao Wu, Yi Luo, et al.
Plos One
|
November 11, 2011
Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells
Ayako Nakano, Daisuke Tsuji, Hirokazu Miki, et al.
Current Research in Translational Medicine
|
July 5, 2020
CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
Yongxian Hu, Elaine Tan Su Yin, Yingying Yang, et al.
The New England Journal of Medicine
|
April 24, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
Yongxian Hu, Mingming Zhang, Tingting Yang, et al.
Cell Research
|
September 23, 2022
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Yongxian Hu, Yali Zhou, Mingming Zhang, et al.
Journal of Hematology & Oncology
|
May 6, 2020
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
Houli Zhao, Jieping Wei, Guoqing Wei, et al.
American Journal of Hematology
|
May 14, 2026
Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up
Houli Zhao, Zhouning Lin, Haiqiong Zheng, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
British Journal of Haematology
|
September 10, 2011
KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts
Hirokazu Miki, Shuji Ozaki, Shingen Nakamura, et al.
Haematologica
|
June 27, 2020
Reveromycin A, a novel acid-seeking agent, ameliorates bone destruction and tumor growth in multiple myeloma
Keiichiro Watanabe, Ariunzaya Bat-Erdene, Hirofumi Tenshin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 1, 2017
Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Yongxian Hu, Zhao Wu, Yi Luo, et al.
Plos One
|
November 11, 2011
Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells
Ayako Nakano, Daisuke Tsuji, Hirokazu Miki, et al.
Current Research in Translational Medicine
|
July 5, 2020
CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges
Yongxian Hu, Elaine Tan Su Yin, Yingying Yang, et al.
The New England Journal of Medicine
|
April 24, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
Yongxian Hu, Mingming Zhang, Tingting Yang, et al.
Cell Research
|
September 23, 2022
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Yongxian Hu, Yali Zhou, Mingming Zhang, et al.
Journal of Hematology & Oncology
|
May 6, 2020
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study
Houli Zhao, Jieping Wei, Guoqing Wei, et al.
American Journal of Hematology
|
May 14, 2026
Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up
Houli Zhao, Zhouning Lin, Haiqiong Zheng, et al.
Page
of 5